(Press-News.org) Bethesda, MD (Aug. 28, 2014) — A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to a new study in Gastroenterology1, the official journal of the American Gastroenterological Association.
When added to the standard chemotherapy treatment — fluorouracil and leucovorin — adjuvant irinotecan therapy improved overall survival rates for patients with the CpG island methylator phenotype (CIMP). CIMP is seen in about 10 to 20 percent of colorectal cancers. Patients with CIMP-negative tumors, however, exhibited significant harm from the addition of irinotecan — overall survival was 68 percent compared with 78 percent for those receiving the standard treatment alone.
"Our results serve as an example that the molecular characterization of individual tumors may help to determine the most appropriate treatment for patients with colon cancer," said lead study author Stacey Shiovitz, MD, from the department of medicine, University of Washington, Seattle, WA, and the clinical research division of Fred Hutchinson Cancer Research Center, also in Seattle. "Based on our findings, identification of a tumor's CIMP status should play a greater role in the clinical setting."
Researchers analyzed data from patients with stage III colon cancer randomly assigned to groups given fluorouracil and leucovorin or adjuvant irinotecan after surgery, from April 1999 through April 2001. Patients were followed for eight years. Patients with CIMP-positive tumors demonstrated a trend toward improved overall survival when treated with irinotecan versus the standard treatment alone, 69 percent versus 56 percent, respectively. Results were most pronounced among patients with stage III CIMP-positive, mismatch repair intact (MMR-I) colon cancer.
No significant associations or interactions between CIMP and KRAS or BRAF mutations were observed, suggesting that the effectiveness of this treatment is not influenced by KRAS/BRAF mutation status.
"This analysis serves to increase our understanding of which subset of patients might benefit from irinotecan adjuvant therapy. This research is an important step in the medical community's work to classify tumors into groups that would result in optimized treatment strategies, thus delivering a higher level of personalized care to patients," added Dr. Shiovitz.
Future studies are needed to better understand the origin of the CIMP phenotype and to test these findings in a larger subset.
INFORMATION:
Colon cancer continues to be a major cause of cancer-related death. To learn more about colon cancer, view AGA's patient brochure.
This study was supported by funding from the Lattner Family Foundation, RACE Charities, Burroughs Wellcome Fund and National Institutes of Health.
1 Shiovitz et al. CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer. Gastroenterology 2014: 147(3): 637-645.
About the AGA Institute
The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to include 17,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization.
About Gastroenterology
Gastroenterology, the official journal of the AGA Institute, is the most prominent scientific journal in the specialty and is in the top 1 percent of indexed medical journals internationally. The journal publishes clinical and basic science studies of all aspects of the digestive system, including the liver and pancreas, as well as nutrition. The journal is abstracted and indexed in Biological Abstracts, Current Awareness in Biological Sciences, Chemical Abstracts, Current Contents, Excerpta Medica, Index Medicus, Nutrition Abstracts and Science Citation Index. For more information, visit http://www.gastrojournal.org.
Like AGA and Gastroenterology on Facebook.
Join AGA on LinkedIn.
Follow us on Twitter @AmerGastroAssn.
Check out our videos on YouTube.
Drug shows promise for subset of stage III colon cancer patients
2014-08-28
ELSE PRESS RELEASES FROM THIS DATE:
Saddam Hussein -- a sincere dictator?
2014-08-28
Are political speeches manipulative and strategic? They could be – when politicians say one thing in public, and privately believe something else, political scientists say. Saddam Hussein's legacy of recording private discussions offers researchers a fascinating insight: both into the consistency of this controversial leader's public and private rhetoric and into the bigger picture of conflict and national security during his regime. New research into the similarity between political leaders' public statements and private beliefs, using Saddam Hussein's transcripts, appeared ...
Ontario has one of the highest rates of IBD in the world
2014-08-28
OTTAWA, August 28, 2014 – One in every 200 Ontarians has been diagnosed with inflammatory bowel disease (IBD), with the number of people living with the disease increasing by 64 per cent between 1999 and 2008, according to a study by researchers at the Institute for Clinical Evaluative Sciences (ICES), the Children's Hospital of Eastern Ontario (CHEO), and the Ottawa Hospital Research Institute. That puts Ontario in the 90th percentile for IBD prevalence in the world.
The study, published this week in Inflammatory Bowel Diseases, is the first and largest Canadian study ...
How does it feel to be old in different societies?
2014-08-28
People aged 70 and over who identify themselves as 'old' feel worse about their own health in societies where they perceive they have lower value than younger age groups.
New research from psychologists at the University of Kent, titled 'Being old and ill' across different countries: social status, age identification and older people's subjective health, used data from the European Social Survey. Respondents, who were all aged 70 and over, were asked to self-rate their health.
The researchers found that those living in societies where older people have lower status were ...
Arthritis patients failing to take expensive medication, according to new research
2014-08-28
Twenty seven per cent of rheumatoid arthritis patients in the study who were on a class of drugs known as anti-TNF therapies did not take them as prescribed in the first six months. Patients from Manchester Royal Infirmary were among those from 60 hospitals around the UK involved in the study.
Researchers from the Arthritis Research UK Centre for Genetics and Genomics at The University of Manchester, who led the study, warned that failure to take the drugs correctly, known as 'non-adherence', reduced their effectiveness and may lead to a worsening of patients' disease. ...
Research demonstrates potential method to better control lung cancer using radiotherapy
2014-08-28
Manchester scientists are working out how to safely increase the radiotherapy dose given to lung cancer patients – potentially offering improved local control and survival.
Standard treatment for locally advanced non-small cell lung cancer is a combination of radiotherapy and chemotherapy. Traditionally this is planned in a one-size-fits-all manner but the radiation dose may not always be enough to stop tumour growth.
The potential to increase the radiation dose to the cancerous tissue varies between patients and depends on the size and location of the tumour in relation ...
Dyslexic readers have disrupted network connections in the brain
2014-08-28
Philadelphia, PA, August 28, 2014 – Dyslexia, the most commonly diagnosed learning disability in the United States, is a neurological reading disability that occurs when the regions of the brain that process written language don't function normally.
The use of non-invasive functional neuroimaging tools has helped characterize how brain activity is disrupted in dyslexia. However, most prior work has focused on only a small number of brain regions, leaving a gap in our understanding of how multiple brain regions communicate with one another through networks, called functional ...
Study shows where on the planet new roads should and should not go
2014-08-28
More than 25 million kilometres of new roads will be built worldwide by 2050. Many of these roads will slice into Earth's last wildernesses, where they bring an influx of destructive loggers, hunters and illegal miners.
Now, an ambitious study has created a 'global roadmap' for prioritising road building across the planet, to try to balance the competing demands of development and environmental protection.
The map has two components: an 'environmental-values' layer that estimates that natural importance of ecosystems and a 'road-benefits' layer that estimates the potential ...
Nanoscale assembly line
2014-08-28
This news release is available in German. Cars, planes and many electronic products are now built with the help of sophisticated assembly lines. Mobile assembly carriers, on to which the objects are fixed, are an important part of these assembly lines. In the case of a car body, the assembly components are attached in various work stages arranged in a precise spatial and chronological sequence, resulting in a complete vehicle at the end of the line.
The creation of such an assembly line at molecular level has been a long-held dream of many nanoscientists. "It would ...
Paleontology: Oldest representative of a weird arthropod group
2014-08-28
Biologists at Ludwig-Maximilians-Universitaet (LMU) in Munich have assigned a number of 435-million-year-old fossils to a new genus of predatory arthropods. These animals lived in shallow marine habitats and were far less eye-catching than related forms found in Jurassic strata.
Before they sank to the bottom of their shallow marine habitat and were fossilized some 435 million years ago, these arthropods preyed on other denizens of the Silurian seas – although they were not exactly inconspicuous, possessing a bivalved carapace and multiple abdominal limbs. A group of ...
Better classification to improve treatments for breast cancer
2014-08-28
Breast cancer can be classified into ten different subtypes, and scientists have developed a tool to identify which is which. The research, published in the journal Genome Biology, could improve treatments and targeting of treatments for the disease.
Cancer arises due to genetic changes which cause normal cells to develop into tumors. As we learn more about breast cancer, we are seeing that it is not one single disease – the mutations in the genes that cause different cancers are not alike, and this is why tumors respond differently to treatment and grow at different ...